Isomorphic Labs and MSD partner on AI-designed oncology drugs

Isomorphic Labs and MSD announced a research collaboration on November 19 to discover small-molecule drug candidates for an oncology target, according to their joint announcement.
Isomorphic will use its proprietary drug-design engine, IsoDDE, to generate predictions and molecular designs. MSD, known as Merck in the United States and Canada, will supply selected proprietary datasets for the project.
MSD will take responsibility for preclinical and clinical development, manufacturing and commercialization of any resulting products. The announcement does not identify the oncology target or disclose the financial amounts involved.
Isomorphic will receive an upfront payment and could earn additional payments tied to research, development, regulatory and commercial milestones, plus tiered royalties on net sales. It also has an option to help fund development in exchange for higher royalties.
The agreement connects AI-generated molecular designs with a pharmaceutical company's data and development capabilities. It is an early research partnership, not evidence that a resulting treatment has passed clinical trials or received regulatory approval.
Sources and citations
Revision history
Published .